Drug recall · June 14, 2023
Levsin injection recall
Why: CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Levsin injection (hyoscyamine sulfate injection, USP), 0.5 mg per ml in water for Injection, 1 ml Ampule (Box of 5 ampules), Rx Only, Distributed by: Meda pharmaceuticals Inc. (a Viatris company) Somerset New Jersey 00873-4120, NDC #0037-9001-05
- Lots / codes
Lot #: 101241A, Exp 10/23
- Quantity
- 2,736 boxes
- Company
- Viatris Inc, Canonsburg, PA
- Distribution
- Product was distributed to 10 distributors who may have further distribute the product to the retail level.
- Initiated
- May 25, 2023 · Voluntary: Firm initiated
- Classified
- June 5, 2023
- Reported
- June 14, 2023
- Ended
- April 11, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hyoscyamine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.